



Join Keystone Symposia  
for the 2016 conference on:

# HIV Vaccines

**March 20–24, 2016**

**Resort at Squaw Creek | Olympic Valley, California | USA**

Scientific Organizers:

David C. Montefiori and Mario Roederer

*Joint with the conference on: **HIV Persistence – Pathogenesis and Eradication***

*Evidence from multiple passive transfer experiments in non-human primates, as well as from studies of immunologic correlates of modest efficacy in the RV144 Thai trial, support the notion that both neutralizing and non-neutralizing antibodies have potential to prevent infection. Major advances have been made in understanding the epitopes, structures and evolutionary pathways of broadly neutralizing antibodies, leading to new avenues to pursue for vaccine design. The extraordinary breadth and potency of some recently discovered neutralizing antibodies has generated additional interest in potential therapeutic applications, including cure strategies. There has also been a steady increase in knowledge of other types of antiviral antibodies and their effector functions that may be important for vaccines. This meeting aims to cover a range of topics including: 1) Initial virus transmission events for vaccine intervention, 2) Non-neutralizing antibody correlates of sterilizing immunity; 3) Epitopes, structures and ontogeny of broadly neutralizing antibodies; 4) Novel vaccine concepts for broadly neutralizing antibody induction; and 5) Immunotherapy. Emphasis will be placed on recent unpublished findings in key areas that hold the greatest promise for rapid progress toward an effective vaccine.*

*Session Topics:*

- Acute HIV Infection and Initial Transmission Events (Joint)
- Immunologic Correlates of Sterilizing Immunity
- Epitopes, Structures and Ontogeny of Broadly Neutralizing Antibodies
- Vaccine Concepts I & II
- Pathways Leading to Long-Term Protective Immunity Against HIV-1
- Immunotherapy (Joint)
- Bridging Innate and Acquired Immunity



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

**Scholarship & Discounted Abstract Deadline: Nov 19, 2015**

**Abstract Deadline: Dec 17, 2015**

**Discounted Registration Deadline: Jan 21, 2016**

For additional details, visit [www.keystonesymposia.org/16X8](http://www.keystonesymposia.org/16X8).

**KEYSTONE SYMPOSIA™**  
on Molecular and Cellular Biology

*Accelerating Life Science Discovery*

[www.keystonesymposia.org/meetings](http://www.keystonesymposia.org/meetings) | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## HIV Vaccines (X8)

**Scientific Organizers: David C. Montefiori and Mario Roederer**

*Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.*

## HIV Persistence: Pathogenesis and Eradication (X7)

**Scientific Organizers: David M. Margolis, Satya Dandekar and Susana T. Valente**

**March 20-24, 2016 • Resort at Squaw Creek • Olympic Valley, California, USA**

*Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.*

Global Health Travel Award Deadline: October 20, 2015 / Abstract & Scholarship Deadline: November 19, 2015 / Abstract Deadline: December 17, 2015 / Discounted Registration Deadline: January 21, 2016

### SUNDAY, MARCH 20

#### Arrival and Registration

### MONDAY, MARCH 21

#### Welcome and Keynote Address (Joint)

**Anthony S. Fauci**, NIAID, National Institutes of Health, USA  
*Combination Approaches to Prevent and Eradicate HIV Infection*

#### Acute HIV Infection and Initial Transmission Events (Joint)

**George M. Shaw**, University of Pennsylvania, USA  
*Molecular Events Associated with HIV-1 Transmission and Acute Infection*

**Joseph Eron**, University of North Carolina School of Medicine, USA  
*AHI, Therapy and Persistence*

**Giuseppe Pantaleo**, Centre Hospitalier Universitaire Vaudois, Switzerland  
*Therapeutic Interventions in Acute HIV Infection*

#### Short Talk(s) Chosen from Abstracts

#### Workshop: Requirements for bnAb Induction (X8)

##### Short Talks Chosen from Abstracts

#### Immunologic Correlates of Sterilizing Immunity (X8)

**Merlin L. Robb**, Walter Reed Army Institute of Research, USA  
*Optimizing Quality and Durability of Immune Responses: Insights from RV 144 Follow-up Studies*

**Genoveffa Franchini**, NCI, National Institutes of Health, USA  
*Correlates of Protection in Nonhuman Primate Models of SIV and SHIV Infection*

**Georgia D. Tomaras**, Duke University Medical Center, USA  
*Key Epitopes and Ig Isotypes for Protection Against HIV-1*

#### Short Talk Chosen from Abstracts

#### Mechanisms of Persistent Infection (X7)

**Jonathan Karn**, Case Western Reserve University, USA  
*Epigenetic Control of HIV Latency*

**Melanie M. Ott**, University of California, San Francisco, USA  
*New Therapeutic Targets in Latent HIV Infection*

**John M. Coffin**, Tufts University, USA  
*Cellular Proliferation and HIV Persistence*

**Susana T. Valente**, Scripps Florida, USA  
*Eradication without Reactivation*

**Andrew P. Rice**, Baylor College of Medicine, USA  
*Transcription Complex Regulation and HIV Latency*

#### Short Talk Chosen from Abstracts

### Poster Session 1

### TUESDAY, MARCH 22

#### Epitopes, Structures and Ontogeny of Broadly Neutralizing Antibodies (X8)

**Pamela J. Bjorkman**, California Institute of Technology, USA  
*Structure-Based Design of Improved Antibodies Against HIV*  
**William Schief**, IAVI and The Scripps Research Institute, USA  
*Epitope-Focused HIV Vaccine Design*

**Dennis R. Burton**, The Scripps Research Institute, USA  
*Broadly Neutralizing Antibodies to Guide HIV Vaccine Design*

**Jinal Nomathemba Bhiman**, National Institute for Communicable Diseases and WITS University, South Africa  
*Viral Variants that Initiate and Drive Maturation of Broadly Neutralizing Antibodies*

#### Short Talk(s) Chosen from Abstracts

#### Reservoirs and Persistence I (X7)

**Janice E. Clements**, Johns Hopkins University, USA  
*CNS and Other Reservoirs in SIV Infection*

**Satya Dandekar**, University of California, Davis, USA  
*Early Establishment of HIV Reservoirs*

**J. Victor Garcia-Martinez**, University of North Carolina at Chapel Hill, USA  
*Studies of Anti-Latency Therapy in the Humanized Mouse Model*

#### Short Talk(s) Chosen from Abstracts

#### Workshop 1: Obstacles to Cure (X7)

##### Short Talks Chosen from Abstracts

#### Vaccine Concepts I (X8)

**David C. Montefiori**, Duke University Medical Center, USA  
*Magnitude and Breadth of Neutralization Required for Vaccine Protection Against HIV*

**John P. Moore**, Weill Medical College of Cornell University, USA  
*How to Make and Use Multiple Native-Like SOSIP Trimers for Vaccine and Structural Studies*

**Bette T. Korber**, Los Alamos National Laboratory, USA  
*HIV Vaccine Antigen Design*

#### Short Talk Chosen from Abstracts

#### Auxiliary Genes and Host Restriction Factors (X7)

**Alan N. Engelman**, Dana-Farber Cancer Institute, USA  
*HIV Integration and Viral Regulation*

**Stephen P. Goff**, Columbia University, USA  
*Retroviral Silencing: Transcriptional and Post-Transcriptional Regulation*

**Michael Emerman**, Fred Hutchinson Cancer Research Center, USA  
*Evolution of Host Antiviral Restriction Factors*

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## HIV Vaccines (X8)

**Scientific Organizers: David C. Montefiori and Mario Roederer**

*Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.*

## HIV Persistence: Pathogenesis and Eradication (X7)

**Scientific Organizers: David M. Margolis, Satya Dandekar and Susana T. Valente**

**March 20-24, 2016 • Resort at Squaw Creek • Olympic Valley, California, USA**

*Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.*

*Global Health Travel Award Deadline: October 20, 2015 / Abstract & Scholarship Deadline: November 19, 2015 / Abstract Deadline: December 17, 2015 / Discounted Registration Deadline: January 21, 2016*

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## HIV Vaccines (X8)

**Scientific Organizers: David C. Montefiori and Mario Roederer**

*Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.*

## HIV Persistence: Pathogenesis and Eradication (X7)

**Scientific Organizers: David M. Margolis, Satya Dandekar and Susana T. Valente**

**March 20-24, 2016 • Resort at Squaw Creek • Olympic Valley, California, USA**

*Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.*

*Global Health Travel Award Deadline: October 20, 2015 / Abstract & Scholarship Deadline: November 19, 2015 / Abstract Deadline: December 17, 2015 / Discounted Registration Deadline: January 21, 2016*

### Short Talk Chosen from Abstracts

#### Poster Session 2

#### WEDNESDAY, MARCH 23

##### Pathways Leading to Long-Term Protective Immunity Against HIV-1 (X8)

**Bali Pulendran**, Emory University, USA  
*Signaling Mechanisms*

**W. Ripley Ballou**, GlaxoSmithKline Vaccines, Belgium  
*Inducing Long-Term Protection with Vaccines*

**Richard A. Koup**, NIAID, National Institutes of Health, USA  
*T Cell Help*

**Speaker to be Announced**

##### Short Talk(s) Chosen from Abstracts

##### Antiviral Host Response and Inflammation (X7)

**Nicolas Chomont**, University of Montreal, Canada  
*Homeostasis of the Latent HIV Reservoir*

**Yasmine Belkaid**, NIAID, National Institutes of Health, USA  
*Talk Title to be Announced*

**Zhi Hong**, GlaxoSmithKline, USA  
*Manipulating the Host Response in Persistence HIV Infection*

**Ivona Pandrea**, University of Pittsburgh, USA  
*Natural Persistence of SIV*

##### Short Talk(s) Chosen from Abstracts

#### Workshop 2 (X7)

##### Short Talks Chosen from Abstracts

#### Vaccine Concepts II (X8)

**Mario Roederer**, NIAID, National Institutes of Health, USA  
*Passive Immunization in the SIV Model*

**Barton F. Haynes**, Duke University Medical Center, USA  
*B Cell Lineage Approach to Broadly Neutralizing Antibodies*

**Peter D. Kwong**, NIAID, National Institutes of Health, USA  
*Structure-Based Immunogen Design*

##### Short Talk Chosen from Abstracts

#### Cure Studies in Models and Man (X7)

**Nancie M. Archin**, University of North Carolina, Chapel Hill, USA  
*Update on Studies in Man*

**John W. Mellors**, University of Pittsburgh School of Medicine, USA  
*Biomarkers of HIV Persistence and Response to Therapeutic Interventions*

**Jerome A. Zack**, University of California, Los Angeles, USA  
*Modeling CARs to Clear Infection in the Humanized Mouse Model*

##### Short Talk Chosen from Abstracts

#### Poster Session 3

#### THURSDAY, MARCH 24

##### Keynote Address (Joint)

**John R. Mascola**, NIAID, National Institutes of Health, USA  
*Broadly Neutralizing Antibodies for HIV Prevention and Treatment*

##### Immunotherapy (Joint)

**David D. Ho**, Rockefeller University, USA  
*Bispecific Antibodies*

**Michael Farzan**, The Scripps Research Institute, USA  
*AAV-Expressed eCD4-Ig Can Protect Macaques from Robust SHIV-AD8 Challenges*

**David M. Margolis**, University of North Carolina at Chapel Hill, USA  
*Enlisting Effector Cells to Clear Latent HIV Infection*

**Louis J. Picker**, Oregon Health & Science University, USA  
*CMV-Based HIV Vaccines for HIV Prevention and Clearance*

##### Short Talk(s) Chosen from Abstracts

##### Bridging Innate and Acquired Immunity (X8)

**Jeffrey V. Ravetch**, Rockefeller University, USA  
*Optimizing Antibody-FcR Interactions*

**Margaret Ellen Ackerman**, Dartmouth College, USA  
*FcR Effector Mechanisms*

**George K. Lewis**, University of Maryland, USA  
*Qualitative and Quantitative Variables that Contribute to Fc-mediated Protection Against HIV-1*

##### Reservoirs & Persistence II (X7)

**Sarah E. Palmer**, Westmead Millennium Institute for Medical Research, Australia  
*Distinguishing Functional Proviral Genomes from Residual DNA*

**Vicente Planelles**, University of Utah, USA  
*Novel Classes of HIV Latency-Reversing Agents*

**Daria J. Hazuda**, Merck Research Laboratories, USA  
*Combination Therapy with HIV Latency-Reversing Agents*

##### Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X8)

##### Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X7)

#### FRIDAY, MARCH 25

##### Departure